- Home
- CMA vs VRNA Comparison
CMA vs VRNA Comparison
Compare CMA & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- VRNA
- Stock Information
- Founded
- CMA 1849
- VRNA 2005
- Country
- CMA United States
- VRNA United Kingdom
- Employees
- CMA N/A
- VRNA N/A
- Industry
- CMA Major Banks
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- VRNA Health Care
- Exchange
- CMA Nasdaq
- VRNA Nasdaq
- Market Cap
- CMA 7.7B
- VRNA 8.3B
- IPO Year
- CMA N/A
- VRNA 2017
- Fundamental
- Price
- CMA $68.00
- VRNA $105.30
- Analyst Decision
- CMA Hold
- VRNA Buy
- Analyst Count
- CMA 21
- VRNA 11
- Target Price
- CMA $62.50
- VRNA $114.10
- AVG Volume (30 Days)
- CMA 2.6M
- VRNA 7.7M
- Earning Date
- CMA 07-18-2025
- VRNA 08-07-2025
- Dividend Yield
- CMA 4.17%
- VRNA N/A
- EPS Growth
- CMA 15.05
- VRNA N/A
- EPS
- CMA 5.21
- VRNA N/A
- Revenue
- CMA $3,215,000,000.00
- VRNA $118,535,000.00
- Revenue This Year
- CMA $7.26
- VRNA $893.95
- Revenue Next Year
- CMA $2.83
- VRNA $73.76
- P/E Ratio
- CMA $13.06
- VRNA N/A
- Revenue Growth
- CMA N/A
- VRNA N/A
- 52 Week Low
- CMA $48.12
- VRNA $18.51
- 52 Week High
- CMA $73.45
- VRNA $105.45
- Technical
- Relative Strength Index (RSI)
- CMA 69.05
- VRNA 71.22
- Support Level
- CMA $59.96
- VRNA $104.58
- Resistance Level
- CMA $65.94
- VRNA $105.30
- Average True Range (ATR)
- CMA 1.76
- VRNA 0.58
- MACD
- CMA 0.39
- VRNA -0.30
- Stochastic Oscillator
- CMA 98.17
- VRNA 98.94
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.